课题基金 / 基金详情

ADRIAMYCIN PLUS ZINECARD V NO TREATMENT IN ADVANCED BREAST CA AFTER 6 CYCLES CAF

ADRIAMYCIN PLUS ZINECARD V NO TREATMENT IN ADVANCED BREAST CA AFTER 6 CYCLES CAF
ADRIAMYCIN PLUS ZINECARD V 在 6 个周期 CAF 后未在高级乳腺癌 CA 中进行治疗
批准号：
6246869
负责人：
JAMES SPEYER
金额：
$2.39万
依托单位：
NEW YORK UNIVERSITY SCHOOL OF MEDICINE
依托单位国家：
美国
项目类别：
财政年份：
1997
资助国家：
美国
项目状态：
已结题
起止时间：
1997-02-12 至 1997-11-30
来源：
https://reporter.nih.gov/project-details/6246869
关键词：
breast neoplasms cardiovascular agents chemoprevention clinical research congestive heart failure cyclophosphamide doxorubicin drug screening /evaluation human subject human therapy evaluation

项目摘要

项目成果

JAMES SPEYER的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
The primary objectives of this randomized Phase IIIb two armed trial are to 1) evaluate whether continuing therapy with Adriamycin and dexrazoxane (which is cardioprotective) prolongs time to progression in patients with locally advanced or metastatic breast cancer who are stable or in response after receiving six courses of front-line CAF chemotherapy compared to similar patients whose chemotherapy has been interrupted after 6 courses of chemotherapy; 2) whether continuing therapy with these agents prolongs time to disease progression, development of CHF, or death compared to patients who had chemotherapy interrrupted; 3) to evaluate the effect on performance status, tumor-related symptoms and safety of both agents.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Protocol Review and Monitoring
WEEKLY ONE HOUR PACLITAXEL IN REFRACTORY METASTATIC BREAST CANCER
WEEKLY ONE HOUR PACLITAXEL IN REFRACTORY METASTATIC BREAST CANCER
DEXRAZOXANE, DOXORUBICIN & ESCALATING DOSES OF PACLITAXEL IN ADVANCED BREAST CA
海外基金